Trinity Biotech (NASDAQ:TRIB) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIBFree Report) in a research note released on Sunday morning. The brokerage issued a buy rating on the stock.

Trinity Biotech Trading Up 3.0 %

TRIB stock opened at $2.04 on Friday. The stock has a market capitalization of $15.54 million, a PE ratio of -0.54 and a beta of 1.22. Trinity Biotech has a 12-month low of $1.85 and a 12-month high of $6.20. The stock’s 50 day simple moving average is $2.27 and its 200 day simple moving average is $2.44.

Trinity Biotech (NASDAQ:TRIBGet Free Report) last released its quarterly earnings data on Wednesday, January 31st. The company reported ($0.90) earnings per share (EPS) for the quarter. The company had revenue of $14.68 million during the quarter. On average, research analysts predict that Trinity Biotech will post -2.95 earnings per share for the current year.

Institutional Investors Weigh In On Trinity Biotech

Hedge funds have recently added to or reduced their stakes in the stock. Whitefort Capital Management LP increased its stake in shares of Trinity Biotech by 1,067.8% in the 1st quarter. Whitefort Capital Management LP now owns 409,517 shares of the company’s stock worth $434,000 after purchasing an additional 374,449 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Trinity Biotech in the 1st quarter worth $40,000. Renaissance Technologies LLC increased its stake in shares of Trinity Biotech by 2.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,503,336 shares of the company’s stock worth $1,842,000 after purchasing an additional 34,900 shares in the last quarter. Finally, Atria Wealth Solutions Inc. bought a new position in Trinity Biotech in the 1st quarter worth $27,000. 78.97% of the stock is currently owned by hedge funds and other institutional investors.

Trinity Biotech Company Profile

(Get Free Report)

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Further Reading

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.